Apremilast Pharmacogenomics in Russian Patients with Moderate-to-Severe and Severe Psoriasis.

ABSTRACT: One of the target drugs for plaque psoriasis treatment is apremilast, which is a selective phosphodiesterase 4 (PDE4) inhibitor. In this study, 34 moderate-to-severe and severe plaque psoriasis patients from Russia were treated with apremilast for 26 weeks. This allowed us to observe the effectiveness of splitting patient cohorts based on clinical outcomes, which were assessed using the Psoriasis Area Severity Index (PASI). In total, 14 patients (41%) indicated having an advanced outcome with delta PASI 75 after treatment; 20 patients indicated having moderate or no effects. Genome variability was investigated using the Illumina Infinium Global Screening Array. Genome-wide analysis revealed apremilast therapy clinical outcome associations at three compact genome regions with undefined func

SUBMITTER: Verbenko DA 

PROVIDER: S-EPMC7823747 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature